What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Federico Cappuzzo mainly investigates Lung cancer, Internal medicine, Oncology, Epidermal growth factor receptor and Gefitinib.
His Lung cancer study incorporates themes from Cancer, Adenocarcinoma, Prospective cohort study and Carcinoma.
His research in Internal medicine tackles topics such as Surgery which are related to areas like ROS1.
His Oncology study combines topics from a wide range of disciplines, such as Immunohistochemistry, Tolerability and Survival analysis.
His studies deal with areas such as Gene dosage, Cancer research and KRAS as well as Epidermal growth factor receptor.
He has included themes like Endocrinology, Tyrosine kinase, Erlotinib, Tyrosine-kinase inhibitor and Growth factor receptor in his Gefitinib study.
His most cited work include:
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (3639 citations)
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer (1817 citations)
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis (1560 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Oncology, Lung cancer, Chemotherapy and Cancer research.
Internal medicine and Surgery are frequently intertwined in his study.
His work in the fields of Oncology, such as Erlotinib, intersects with other areas such as In patient.
The Lung cancer study combines topics in areas such as Epidermal growth factor receptor and Adenocarcinoma.
The study incorporates disciplines such as Gastroenterology and Hazard ratio in addition to Chemotherapy.
His research in Cancer research intersects with topics in Bioinformatics, Tyrosine kinase, Carcinoma, Exon and Gene dosage.
He most often published in these fields:
- Internal medicine (71.64%)
- Oncology (65.82%)
- Lung cancer (52.00%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (71.64%)
- Oncology (65.82%)
- Lung cancer (52.00%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Lung cancer, Carboplatin and Chemotherapy.
Internal medicine connects with themes related to Gastroenterology in his study.
His studies in Oncology integrate themes in fields like Cancer, Disease and Maintenance therapy.
His work deals with themes such as Pembrolizumab, KRAS, Histology and Immunohistochemistry, which intersect with Lung cancer.
His Carboplatin research includes elements of Atezolizumab and Paclitaxel.
The various areas that Federico Cappuzzo examines in his Chemotherapy study include Dacomitinib and Drug resistance.
Between 2018 and 2021, his most popular works were:
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial (288 citations)
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. (236 citations)
- Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial (52 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Progression-free survival and Hazard ratio.
His Oncology study incorporates themes from Adverse effect and Cohort.
His Lung cancer research incorporates themes from Pembrolizumab and KRAS.
His Progression-free survival research is multidisciplinary, incorporating elements of Cancer research, Mutation, Point mutation, Afatinib and Performance status.
The concepts of his Hazard ratio study are interwoven with issues in Carboplatin, Atezolizumab, Chemotherapy and Stage.
His Carboplatin research includes themes of Maintenance therapy and Phases of clinical research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
